Price regulation and parallel imports of pharmaceuticals
نویسندگان
چکیده
منابع مشابه
Wholesale Price Discrimination and Parallel Imports
We develop a model of vertical pricing in which an original manufacturer sets wholesale prices in two markets integrated at the distributor level by parallel imports (PI). In this context we show that if competition policy requires uniform wholesale prices across locations it would push retail prices toward convergence as transportation costs fall. However, these retail prices could be higher t...
متن کاملPrice Regulation of Pharmaceuticals: A Policy Experiment
What does the demand for pharmaceuticals look like? How effectively does a price cut control pharmaceutical expenditure? To shed light on these questions, I estimate the demand for antihypertensive drugs in Korea (2003-2007) using NLM. The estimation results are following. 1) Physicians are not sensitive to price differences and the price elasticity of the original drugs is further reduced afte...
متن کاملPharmaceuticals: Reference Pricing or Price Cap Regulation?
We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel dataset, cov...
متن کاملParallel imports and innovation in an emerging economy: the case of Indian pharmaceuticals.
This paper studies the impact of the re-importation of imitated pharmaceuticals as a by-product of an open policy toward parallel import (PI) on process innovation. Foreign investment by a firm to exploit a new unregulated market with weak intellectual property rights can give rise to imitation. These products can potentially re-enter the original country when PI is allowed influencing research...
متن کاملParallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries
The poorest nations of the world suffer from extreme disease burdens, which golargely untreated because weak incomes and the prevailing system of intellectualproperty rights fail to provide sufficient incentives to develop new treatments anddistribute them at low cost. Recent price reductions for HIV/AIDS drugs are encouragingbut offer only a limited solution. We discuss the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Public Economics
سال: 2015
ISSN: 0047-2727
DOI: 10.1016/j.jpubeco.2015.08.002